• Chat
  • Dashboard
    • Feedback
    • Log in
    Log inGet Started

    Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US - Bloomberg.com

    AI Summary1 min read

    TL;DR

    Novo Nordisk has reduced the cash-pay price for its obesity and diabetes drugs Wegovy and Ozempic to $349 per month, undercutting competitor Eli Lilly's pricing in the US.

    Tags

    Novo NordiskWegovyOzempicobesity drugprice cut
    1. Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US  Bloomberg.com
    2. Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month  CNBC
    3. Novo Nordisk further lowers prices for weight loss, diabetes drugs for those who pay cash  CNN
    4. Cash price for popular weight loss drug Wegovy dropping 30% Monday, manufacturer says  abcnews.go.com
    5. Drugmaker cuts prices for Ozempic, Wegovy. Here's how much you will pay.  USA Today

    Monday, November 17, 2025 1:03 PM

    Visit Website
    website-logo

    Top stories - Google News

    Google News

    channel icon
    Related Articles

    How foreign student enrollment is shifting in the U.S., in 6 charts - The Washington Post

    Nov 17, 2025

    The flop that finally flew: why did it take 40 years for Sondheim’s Merrily We Roll Along to soar? - The Guardian

    Nov 17, 2025

    Latest science news: Comet 3I/ATLAS new images | China’s astronauts stranded | AI dead end? - Live Science

    Nov 17, 2025

    Paradox Interactive parts ways with Cities: Skylines studio after over 15 years, as publisher's misfortunes continue - Eurogamer

    Nov 17, 2025
    xgithub
    logo

    Copyright © 2022-2025 - Aetos.AI